CONMED vs Embecta
CONMED reported revenue of $1.4 billion in fiscal 2025, 1.3 times Embecta's $1.1 billion in fiscal 2025. CONMED's revenue grew 5.2% in its latest year, and Embecta's fell 3.8%. CONMED had an operating margin of 7.5%, against 22.4% at Embecta. Free cash flow was $151 million at CONMED and $182 million at Embecta. Their fiscal years end in different months (December 31 and September 30), so the periods don't line up exactly.
Side by side
| CONMED | Embecta | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Sep 30, 2025 |
| Revenue | $1.4B | $1.1B |
| Revenue growth | 5.2% | −3.8% |
| Revenue growth a year, last 5 years | 9.8% | −0.1% |
| Gross margin | 54.6% | 62.6% |
| Operating margin | 7.5% | 22.4% |
| Net margin | 3.4% | 8.8% |
| Free cash flow | $151M | $182M |
| Free cash flow margin | 11.0% | 16.9% |
| Return on capital | 3.7% | 29.3% |
| Net debt to EBITDA | 5.1x | 4.3x |
| Dividends and buybacks | $25M | $35M |
| Change in diluted share count | −0.0% | 1.0% |
| Last close | $46.38 | $6.19 |
| P/E at the last close | 30.7× | 4.2× |
| Insider trades, last 12 months | sold $10,591 | bought $557,850, sold $37,003 |
| Piotroski F-score | 6 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CONMEDEmbecta
Operating margin
Percent of revenue
CONMEDEmbecta
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CONMEDEmbecta